Genmab US
Genmab US is recorded as a service provider in 8 clinical trials. Explore its recorded services, study phases and therapeutic areas, with trial-level operational learnings where available.
Clinical trial experience
Showing 8 of 8 trials · Latest update first
A Phase 1b/2, Open-Label, Safety and Efficacy Study of Epcoritamab (GEN3013; DuoBody®-CD3xCD20) in Relapsed/Refractory Chronic Lymphocytic Leukemia and Richter’s Syndrome
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Phase 2, Open-label, Multicohort, Study of Rinatabart Sesutecan (Rina S) in Participants With Advanced Gastrointestinal (GI) Cancers
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A First-in-Human, Open-label, Dose-escalation Trial With Expansion Cohorts to Evaluate Safety and Anti-tumor Activity of GEN1042 in Subjects With Malignant Solid Tumors
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Prospective, Open-Label, Randomized, Phase 3 Trial of Acasunlimab (GEN1046) in Combination With Pembrolizumab Versus Docetaxel in Subjects With PD-L1 Positive Metastatic Non-Small Cell Lung Cancer After Treatment With a PD-1/PD-L1 Inhibitor and Platinum-Containing Chemotherapy (ABBIL1TY NSCLC-06)
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A Randomized, Open-Label, Multicenter, Global, Phase 2 Trial to Evaluate the Efficacy and Safety of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) as Monotherapy or in Combination with Lenalidomide as First-Line Therapy for Anthracycline-Ineligible Subjects with Diffuse Large B-Cell Lymphoma
Sponsor Genmab A/S
- Start (EU)
- Latest update
- Estimated end
A first-in-human, open-label, dose escalation trial with expansion cohorts to evaluate the safety and preliminary efficacy of BNT314 as monotherapy in patients with advanced malignant solid tumors
Sponsor BioNTech SE
- Start (EU)
- Latest update
- Estimated end
A Phase 1/2a, Open-label, Dose Escalation Trial of GEN3017 with Expansion Cohorts in Relapsed or Refractory CD30+ Classical Hodgkin Lymphoma and CD30+ Non-Hodgkin Lymphoma
Sponsor Genmab A/S
- Start (EU)
- Not reported
- Latest update
- Estimated end
First-in-Human, Open-label, Dose-Escalation Trial with Expansion Cohorts to Evaluate the Safety of GEN1053 as Monotherapy and in Combination With an Immunomodulator in Subjects with Malignant Solid Tumors
Sponsor Genmab B.V.
- Start (EU)
- Latest update
- Estimated end
Questions about this trial experience
What services are recorded for Genmab US?
The 2026-10-09 snapshot links Genmab US to 8 distinct CTIS trials. Recorded services include Laboratory services, BIOMARKER ANALYSIS (EXPANSION ONLY), ctDNA testing, Immune phenotyping (PBMC) testing, among 5 recorded service labels. These are study-specific roles, not a complete or independently verified capability catalogue.
Which therapeutic areas and study phases are recorded for Genmab US?
The most frequently recorded therapeutic areas are Solid Tumor Oncology, Gastroenterology, Haematological Malignancies. Recorded phases include Phase 2, Phase 1. Use the filters to inspect the supporting studies; missing tags are not evidence of absent experience.
In which countries are trials linked to Genmab US conducted?
The linked trials record locations in 18 countries, including Spain, Germany, France, Italy, Belgium. These are trial locations, not confirmed office locations or countries where Genmab US delivered services.
What can this page tell me about Genmab US's trial experience?
Browse 8 distinct trials with recorded roles, sponsor names, available study dates and links to CTIS source records. No trial-level operational findings are recorded in this snapshot. Trial counts and findings do not measure the provider’s performance or establish responsibility for study outcomes.
About this data & company names
One current approved profile per CTIS trial. Services reflect recorded roles, not a complete capability catalogue or a performance ranking. Missing tags mean the information was not recorded. Country tags describe trial locations, not the provider’s service territory.
Start is the reported EU start date; latest update is the CTIS publication date; estimated end is the reported global estimate, which may be in the past. Missing dates are shown as “Not reported”. Operational learnings describe the trial as a whole and do not establish the provider’s responsibility.
Clear service synonyms are grouped; otherwise the source label is retained. Service tags show the recorded roles for each trial. This page groups 1 recorded name variant under Genmab US. Legacy brands remain separate unless explicitly matched in the name registry.
View recorded company names
- Genmab US Inc.